Clinuvel Pharmaceuticals (ASX:CUV) used one of the world’s largest dermatology forums to sharpen its profile in pigmentary disorders, presenting new clinical insights and reinforcing the positioning of its lead therapy across both approved and investigational uses.
At the 2026 American Academy of Dermatology Annual Meeting in Denver, attended by roughly 20,000 professionals, the company highlighted advances in vitiligo research alongside long-term safety data in erythropoietic protoporphyria.
Central to the discussion was afamelanotide, the company’s melanocortin analogue, which featured prominently across multiple sessions.
Case studies from the ongoing CUV105 trial showed repigmentation after 20 weeks of treatment when combined with narrowband ultraviolet B phototherapy. Pigmentation was maintained for up to six months after therapy withdrawal in patients with darker skin types, even among those with active disease, a cohort that typically proves difficult to treat.
The broader vitiligo treatment landscape also came under scrutiny, particularly the role of JAK inhibitors.
Presentations indicated that while therapies such as topical ruxolitinib and oral agents like upadacitinib can deliver clinical improvements, they often require prolonged use and are associated with relapse following discontinuation. The data reinforced a growing consensus that sustained maintenance therapy is necessary to preserve repigmentation outcomes.
Alongside pharmacological advances, Clinuvel introduced an AI-driven Vitiligo Visual Algorithm designed to improve the assessment of depigmentation through imaging. The tool aims to address limitations in existing scoring systems, which can introduce significant variability. The company said that further refinement would be undertaken in collaboration with clinicians and patients.
Emerging disciplines such as psychodermatology also featured in the scientific program, with data underscoring the psychological burden of vitiligo. Nearly half of patients in the United States were reported to have at least one mental health comorbidity, highlighting the need for more holistic treatment approaches that extend beyond skin repigmentation alone.
In erythropoietic protoporphyria, Clinuvel reinforced the long-term safety profile of afamelanotide, marketed as SCENESSE. Analysis of five years of treatment in more than 100 patients showed no evidence of drug-related malignancies or adverse effects on skin lesions, supported by a cumulative dataset exceeding 21,000 administered doses.
The company also drew attention to competing therapies in development, including dersimelagon, for which a serious adverse event in a Phase 3 study was disclosed in the discussion but not included in the tabulated results presented to conference attendees.
Beyond clinical data, Clinuvel invested heavily in visibility at the meeting through its Pavilion of Photomedicine, hosting symposia and engaging with stakeholders across academia, clinical practice and patient advocacy.
“CLINUVEL’s presence at AAD 2026 – among 20,000 healthcare professionals – fits perfectly well as we advance the vitiligo program,” said Mr Lachlan Hay, CLINUVEL’s Chief Operating Officer. “It is therefore essential that U.S. dermatologists not only recognise CLINUVEL for its focus on pigmentary disorders and photomedicine but actually see the effects of the drug developed in vitiligo.
“Additionally, it is logical that we have a large presence year-on-year to achieve name recognition as we prepare for entry to the Nasdaq stock exchange.”
“The key takeaway this year is that systemic and oral JAK inhibitors take a long time to produce a positive visible effect and withdrawal of the JAK inhibitor results in relapse in vitiligo,” said Dr Emilie Rodenburger, CLINUVEL’s Director, Global Clinical Affairs.